Qiagen NV
QGEN
查看详细走势图
50.950USD
-0.265-0.52%
收盘 02/06, 16:00（美东）报价延迟15分钟
11.03B总市值
26.20市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.52%
5天
-5.07%
1月
+7.51%
6月
+7.29%
今年开始到现在
+13.11%
1年
+23.25%
查看详细走势图
TradingKey Qiagen NV股票评分
单位: USD 更新时间: 2026-02-06操作建议
Qiagen NV当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名18/392位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价54.16。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Qiagen NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Qiagen NV亮点
亮点风险
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
利润高增长
公司净利润处于行业前列，最新年度总收入2.09B美元
估值低估
公司最新PE估值26.20，处于3年历史低位
机构减仓
最新机构持股153.75M股，环比减少22.76%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值5.10K
分析师目标
根据
18
位分析师
持有
评级
54.159
目标均价
+5.72%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Qiagen NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Qiagen NV简介
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
公司代码QGEN
公司Qiagen NV
CEOBernard (Thierry)
网址https://www.qiagen.com/
相关品种
